These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10326547)

  • 41. [Advances in prostate-specific membrane antigen targeted therapies for prostate cancer].
    Wang W; Mo ZN
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):547-51. PubMed ID: 20608362
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
    Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
    Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
    Theodorescu D; Frierson HF; Sikes RA
    J Urol; 1999 May; 161(5):1442-8. PubMed ID: 10210369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follow-up evaluation of a phase II prostate cancer vaccine trial.
    Tjoa BA; Simmons SJ; Elgamal A; Rogers M; Ragde H; Kenny GM; Troychak MJ; Boynton AL; Murphy GP
    Prostate; 1999 Jul; 40(2):125-9. PubMed ID: 10386473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
    Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.
    O'Keefe DS; Bacich DJ; Heston WD
    Prostate; 2004 Feb; 58(2):200-10. PubMed ID: 14716746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line.
    Grauer LS; Lawler KD; Marignac JL; Kumar A; Goel AS; Wolfert RL
    Cancer Res; 1998 Nov; 58(21):4787-9. PubMed ID: 9809977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
    Pinto JT; Suffoletto BP; Berzin TM; Qiao CH; Lin S; Tong WP; May F; Mukherjee B; Heston WD
    Clin Cancer Res; 1996 Sep; 2(9):1445-51. PubMed ID: 9816319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
    Xiao Z; Adam BL; Cazares LH; Clements MA; Davis JW; Schellhammer PF; Dalmasso EA; Wright GL
    Cancer Res; 2001 Aug; 61(16):6029-33. PubMed ID: 11507047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
    Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Subbarao SA; Kutala VK
    Gene; 2013 Mar; 516(1):76-81. PubMed ID: 23266799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression.
    Su SL; Huang IP; Fair WR; Powell CT; Heston WD
    Cancer Res; 1995 Apr; 55(7):1441-3. PubMed ID: 7882349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correspondence re: Ghosh A and Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539, 2004.
    Cardillo MR; Gentile V; Di Silverio F
    J Cell Biochem; 2004 Nov; 93(4):641-3. PubMed ID: 15389976
    [No Abstract]   [Full Text] [Related]  

  • 58. First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright.
    Lamb AD; Bryant RJ; Mills IG; Hamdy FC
    Eur Urol; 2018 May; 73(5):653-655. PubMed ID: 29458983
    [No Abstract]   [Full Text] [Related]  

  • 59. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
    Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
    Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
    Ikegami S; Tadakuma T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
    Jpn J Cancer Res; 2002 Oct; 93(10):1154-63. PubMed ID: 12417046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.